(Q43496974)

24 November 2017

title

Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517926

4 October 2022

author name string

McLinn SE

3

1 reference

24 November 2017

P. M. Mendelman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517926

4 October 2022

M. A. Del Beccaro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517926

4 October 2022

S. E. McLinn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517926

4 October 2022

W. M. Todd

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1517926

4 October 2022

language of work or name

English

0 references

publication date

1 September 1992

1 reference

The Journal of Pediatrics

24 November 2017

published in

1 reference

24 November 2017

volume

121

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

459-465

1 reference

In vitro activity of U-76,252 (CS-807), a new oral cephalosporin

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

The pharmacokinetics of the oral cephalosporins--a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

In vitro evaluations of U-76,252 (CS-807): antimicrobial spectrum, beta-lactamase stability, and enzyme inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Analysis of Categorical Data by Linear Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

beta-Lactamase-producing Branhamella catarrhalis causing otitis media in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

The effect of prescribed daily dose frequency on patient medication compliance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

Management of otitis media in infants and children: current role of old and new antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2981805-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-3476(05)81805-0

1 reference

24 November 2017

1 reference